| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -34,527 | -27,503 |
| Share-based compensation | 6,055 | 4,343 |
| Depreciation | 121 | 82 |
| Amortization of intangible assets | 41 | 224 |
| Amortization of operating lease right-of-use assets | 395 | 262 |
| Change in fair value of warrants | -511 | -315 |
| Interest income | 34 | - |
| Non-cash interest expense | 210 | 193 |
| Foreign currency transaction loss | -6,218 | -8,091 |
| Other income | 300 | - |
| Prepaid expenses and other current assets | 319 | 155 |
| Research and development incentives receivable | -1,869 | -208 |
| Accounts payable | -1,825 | -1,589 |
| Accrued expenses and other liabilities | -133 | 540 |
| Operating lease liabilities | -549 | -361 |
| Net cash used in operating activities | -23,289 | -15,980 |
| Payments for intangible assets | 300 | 300 |
| Purchase of property and equipment | 20 | 20 |
| Proceeds from out-licensing | 300 | - |
| Net cash used in investing activities | -20 | -320 |
| Proceeds from exercise of warrants | 487 | 487 |
| Proceeds from issuance of ordinary shares | 0 | 0 |
| Transaction costs on issuance of ordinary shares | 199 | 199 |
| Net cash provided by financing activities | 288 | 288 |
| (decrease)/increase in cash and cash equivalents | -23,021 | -16,012 |
| Cash and cash equivalents at beginning of period | 69,802 | - |
| Effect of exchange rate changes on cash | 1,917 | - |
| Cash and cash equivalents at end of period | 48,698 | - |
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)